Volume 11 • Number 8 • August 2010

Recently I attended a “Cardiology conference” designed to recruit more business for a local HMO. Sure, there were enough clinical tips to make the experience resemble an educational opportunity for doctors around the area. Predictably, the emphasis was on surgical intervention for ser
Read More

Volume 11 • Number 7 • July 2010

Writing this edition of my health newsletter aboard an all-you–can-eat-and-drink cruise ship seems a bit dissonant, but I was asked to speak about cutting edge medical concepts to a group onboard; should I tell them that chocolate makes depression worse, not better?1 And that limiting
Read More

Volume 11 • Number 6 • June 2010

Last month’s issue of the Journal Pediatrics validated what many doctors have been saying for years about a higher risk of ADD with pesticides. The journal is in for a fight with Monsanto-like corporations who have hidden the data showing how toxic pesticides are while attacking anyon
Read More

Volume 11 • Number 4 • April 2010

Last month I reported that “probiotaceuticals” are likely going to be the next bubble in pharmaceuticals. Knowing Big Pharma, they will come up with a name like “buggutexx” (I should patent it): “A poorly appreciated truism is that the information contained within the mammalian genome
Read More

Volume 11 • Number 3 • March 2010

We knew it was coming; it was only a matter of time. Ever since the New England J. of Medicine published the article that finally addressed the true mechanism of how cholesterol drugs work, I waited for the other shoe to drop: if regulators agree, the pool of people in the United Stat
Read More

Volume 11 • Number 2 • February 2010

“Until America has learned to love literature not as an amusement, not as a mere doggerel to memorize in college, but for its humanizing and ennobling energy, she will not  have succeeded in that high sense which alone makes a nation out of people; that which raises it from a dead nam
Read More

Volume 11 • Number 1 • January 2010

 “The current compendia [of chemotherapy] lack transparency, cite little current evidence, lack systematic methods to review and update evidence, and are replete with conflict-of-interest issues… The findings would seem to matter. Up to 75% of all uses of cancer therapies are off labe
Read More